Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)

on behalf of Fondazione Italiana Linfomi (FIL)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five-year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5-year progression-free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre-transformation treatment lines and a short time-to-transformation.

Original languageEnglish
Pages (from-to)713-717
Number of pages5
JournalBritish Journal of Haematology
Volume185
Issue number4
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Follicular Lymphoma
Multicenter Studies
Retrospective Studies
Disease-Free Survival
Maintenance
Observation
Biopsy
Therapeutics
Rituximab

Keywords

  • autologous stem cell transplantation
  • composite lymphoma
  • follicular lymphoma
  • histological transformation
  • rituximab maintenance

ASJC Scopus subject areas

  • Hematology

Cite this

@article{60d190e0c1eb4a4e97884c8138c4efb7,
title = "Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)",
abstract = "Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52{\%} (Group 1) and after a FL diagnosis in 48{\%} (Group 2). Five-year overall survival was 84{\%} for Group 1 and 51{\%} for Group 2 (P < 0·001). In Group 1, 5-year progression-free survival was superior after rituximab maintenance compared to observation only (94{\%} vs. 53{\%}, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre-transformation treatment lines and a short time-to-transformation.",
keywords = "autologous stem cell transplantation, composite lymphoma, follicular lymphoma, histological transformation, rituximab maintenance",
author = "{on behalf of Fondazione Italiana Linfomi (FIL)} and Chiara Rusconi and Antonella Anastasia and Annalisa Chiarenza and Luigi Marcheselli and Federica Cavallo and Sara Rattotti and Barbara Botto and Angela Ferrari and Luca Nassi and Chiara Pagani and Erika Meli and Luca Arcaini and Massimo Federico and Giuseppe Rossi",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/bjh.15816",
language = "English",
volume = "185",
pages = "713--717",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL)

AU - on behalf of Fondazione Italiana Linfomi (FIL)

AU - Rusconi, Chiara

AU - Anastasia, Antonella

AU - Chiarenza, Annalisa

AU - Marcheselli, Luigi

AU - Cavallo, Federica

AU - Rattotti, Sara

AU - Botto, Barbara

AU - Ferrari, Angela

AU - Nassi, Luca

AU - Pagani, Chiara

AU - Meli, Erika

AU - Arcaini, Luca

AU - Federico, Massimo

AU - Rossi, Giuseppe

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five-year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5-year progression-free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre-transformation treatment lines and a short time-to-transformation.

AB - Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post-transformation outcome of 176 biopsy-proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five-year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5-year progression-free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre-transformation treatment lines and a short time-to-transformation.

KW - autologous stem cell transplantation

KW - composite lymphoma

KW - follicular lymphoma

KW - histological transformation

KW - rituximab maintenance

UR - http://www.scopus.com/inward/record.url?scp=85065255314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065255314&partnerID=8YFLogxK

U2 - 10.1111/bjh.15816

DO - 10.1111/bjh.15816

M3 - Article

VL - 185

SP - 713

EP - 717

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -